BxC-I17e
- Generic Name
- BxC-I17e
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Brexogen Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06055361
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Arkansas Research Trials, North Little Rock, Arkansas, United States
🇺🇸DermDox Centers for Dermatology, Camp Hill, Pennsylvania, United States
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Brexogen Inc.
- Registration Number
- NCT06055374
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath